GAF is essential for zygotic genome activation and chromatin accessibility in the early Drosophila embryo
- University of Wisconsin-Madison, United States
Abstract
Following fertilization, the genomes of the germ cells are reprogrammed to form the totipotent embryo. Pioneer transcription factors are essential for remodeling the chromatin and driving the initial wave of zygotic gene expression. In Drosophila melanogaster, the pioneer factor Zelda is essential for development through this dramatic period of reprogramming, known as the maternal-to-zygotic transition (MZT). However, it was unknown whether additional pioneer factors were required for this transition. We identified an additional maternally encoded factor required for development through the MZT, GAGA Factor (GAF). GAF is necessary to activate widespread zygotic transcription and to remodel the chromatin accessibility landscape. We demonstrated that Zelda preferentially controls expression of the earliest transcribed genes, while genes expressed during widespread activation are predominantly dependent on GAF. Thus, progression through the MZT requires coordination of multiple pioneer-like factors, and we propose that as development proceeds control is gradually transferred from Zelda to GAF.
Data availability
Sequencing data have been deposited in GEO under accession code GSE152773.
-
GAF is essential for zygotic genome activation and chromatin accessibility in the early Drosophila embryoNCBI Gene Expression Omnibus, GSE152773.
-
Zelda binding in the early Drosophila melanogasterNCBI Gene Expression Omnibus, GSE30757.
-
The Genomic Binding Profile of GAGA Element Associated Factor (GAF) in Drosophila S2 cellsNCBI Gene Expression Omnibus, GSE40646.
-
Targeting of the dosage-compensated male X-chromosome during early Drosophila developmentNCBI Gene Expression Omnibus, GSE133637.
-
Establishment of regions of genomic activity during the Drosophila maternal-to-zygotic transitionNCBI Gene Expression Omnibus, GSE58935.
-
Histone locus regulation by the Drosophila dosage compensation adaptor protein CLAMPNCBI Gene Expression Omnibus, GSE10292.
-
Concentration dependent binding states of the Bicoid Homeodomain ProteinNCBI Gene Expression Omnibus, GSE86966.
-
Continued activity of the pioneer factor Zelda is required to drive zygotic genome activationNCBI Gene Expression Omnibus, GSE121157.
Article and author information
Author details
Melissa M Harrison
Funding
National Institutes of Health (R01GM111694)
- Melissa M Harrison
National Institutes of Health (R35GM136298)
- Melissa M Harrison
Vallee Foundation
- Melissa M Harrison
National Institutes of Health (T32GM007215)
- Marissa M Gaskill
- Tyler J Gibson
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Copyright
© 2021, Gaskill et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 5,150
- views
-
- 608
- downloads
-
- 96
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
GAF is essential for zygotic genome activation and chromatin accessibility in the early Drosophila embryo
eLife 10:e66668.
https://doi.org/10.7554/eLife.66668
Further reading
-
- Chromosomes and Gene Expression
- Neuroscience
Pathogenic variants in subunits of RNA polymerase (Pol) III cause a spectrum of Polr3-related neurodegenerative diseases including 4H leukodystrophy. Disease onset occurs from infancy to early adulthood and is associated with a variable range and severity of neurological and non-neurological features. The molecular basis of Polr3-related disease pathogenesis is unknown. We developed a postnatal whole-body mouse model expressing pathogenic Polr3a mutations to examine the molecular mechanisms by which reduced Pol III transcription results primarily in central nervous system phenotypes. Polr3a mutant mice exhibit behavioral deficits, cerebral pathology and exocrine pancreatic atrophy. Transcriptome and immunohistochemistry analyses of cerebra during disease progression show a reduction in most Pol III transcripts, induction of innate immune and integrated stress responses and cell-type-specific gene expression changes reflecting neuron and oligodendrocyte loss and microglial activation. Earlier in the disease when integrated stress and innate immune responses are minimally induced, mature tRNA sequencing revealed a global reduction in tRNA levels and an altered tRNA profile but no changes in other Pol III transcripts. Thus, changes in the size and/or composition of the tRNA pool have a causal role in disease initiation. Our findings reveal different tissue- and brain region-specific sensitivities to a defect in Pol III transcription.
-
- Biochemistry and Chemical Biology
- Chromosomes and Gene Expression
The mRNA 5'-cap structure removal by the decapping enzyme DCP2 is a critical step in gene regulation. While DCP2 is the catalytic subunit in the decapping complex, its activity is strongly enhanced by multiple factors, particularly DCP1, which is the major activator in yeast. However, the precise role of DCP1 in metazoans has yet to be fully elucidated. Moreover, in humans, the specific biological functions of the two DCP1 paralogs, DCP1a and DCP1b, remain largely unknown. To investigate the role of human DCP1, we generated cell lines that were deficient in DCP1a, DCP1b, or both to evaluate the importance of DCP1 in the decapping machinery. Our results highlight the importance of human DCP1 in decapping process and show that the EVH1 domain of DCP1 enhances the mRNA-binding affinity of DCP2. Transcriptome and metabolome analyses outline the distinct functions of DCP1a and DCP1b in human cells, regulating specific endogenous mRNA targets and biological processes. Overall, our findings provide insights into the molecular mechanism of human DCP1 in mRNA decapping and shed light on the distinct functions of its paralogs.
